#ImmuneCheckpoint
LightNews LightNews
sophiawongyn.bsky.social
Awesome review on combination strategies with ICB #CancerImmunotherapy #ImmuneCheckpoint
pamsharmamdphd.bsky.social Padmanee (Pam) Sharma, MD, PhD @pamsharmamdphd.bsky.social · Nov 25
www.nature.com/articles/s41...

Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Next-generation combination approaches for immune checkpoint therapy - Nature Immunology
In this Review, Sharma and colleagues describe the current landscape of combination therapies and discuss requirements for the development of effective combination strategies.
www.nature.com
November 26, 2024 at 4:16 AM
immunoeditor.bsky.social
This week in #Science #Immunology: Jan Petersen, Jamie Rossjohn, & colleagues have solved the #CrystalStructure of human #LAG3 – #HLADR1 – #peptide complex, a major target of #ImmuneCheckpoint #therapy!
Crystal structure of the human LAG-3–HLA-DR1–peptide complex
The structural basis of how the immune checkpoint molecule LAG-3 binds peptide HLA-II is resolved.
www.science.org
December 13, 2024 at 10:45 PM
drjonlim.bsky.social
The final results of the practice-changing clinical trial in first line treatment of patients with advanced #melanoma: CheckMate 067.

💊 Combination of anti-PD1 + anti-CTLA-4.

#CancerImmunotherapy
#ImmuneCheckpoint
nejm.org NEJM.org @nejm.org · Jan 5
Among patients with advanced melanoma, median overall survival was 72 months with nivolumab plus ipilimumab and was 37 months with nivolumab alone, as compared with 20 months with ipilimumab alone. Full CheckMate 067 trial results: nej.md/4dUqm0g

#MedSky
The New England Journal of Medicine Nivolumab plus Ipilimumab in Advanced Melanoma A PLAIN LANGUAGE SUMMARY Visual representation of an immune checkpoint inhibitor. Read the full Plain Language Summary at NEJM.org.
January 5, 2025 at 9:27 PM
immunologypodcast.com
How do SSRIs affect #ImmuneCheckpoint blockade?

A team at UCLA showed that inhibiting serotonin transporter enhanced T cell antitumor immunity in mouse syngeneic & human xenograft models.

🖇️ bit.ly/43PS5Ls
🗨️ bit.ly/43NmHO0
June 11, 2025 at 10:08 PM
immunoeditor.bsky.social
In #ScienceImmunology last week, Zhang & al reported that the stability & expression of #ImmuneCheckpoint molecule #TIM3 is regulated by palmitoyltransferase DHHC9. Peptidic inhibitor of DHHC9 accelerates TIM-3 degradation & enhances #CARTCell & #NKCell #antitumor immunity!

bit.ly/SI_adp7302
Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity
Targeting TIM-3 palmitoylation mediated by DHHC9 enhances CAR-T cell– and NK cell–based tumor immunotherapy by suppressing immune exhaustion.
bit.ly
November 19, 2024 at 7:51 PM
lozanzi.bsky.social
#WeekendRead! #DendriticCellPower #FirstLove! Wang Zou &co show @nature.com that #NotAllSTATsAreEqual & STAT3 restrains anti-tumor DC functions driven by STAT5. STAT3 degraders protect against advanced, metastatic, & immunecheckpoint blockade-resistant cancers! www.nature.com/articles/s41...
STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity - Nature
Immune checkpoint blockade activates T cell immunity by reprogramming the STAT3 and STAT5 transcriptional pathways in dendritic cells, and STAT3 degradation is effective for treating tumours...
www.nature.com
May 18, 2025 at 3:46 PM
iatlas-cri.bsky.social
New analysis module!📊

Explore the prevalence, variety and distribution of predicted neoantigens in datasets of response to #ImmuneCheckpoint Inhibitors therapy #Immunotherapy #immunogenomics
November 26, 2024 at 9:01 PM
labsoap.bsky.social
This week #JournalClub @labsoap.bsky.social #LAG3 #immunecheckpoint @cellpress.bsky.social www.cell.com/cell/fulltex...
Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs
This study uncovers the molecular mechanism of LAG3 activation upon ligand engagement and its regulation by non-degradative polyubiquitination within the tumor microenvironment. The findings highlight...
www.cell.com
June 16, 2025 at 2:54 PM
alicefrolov.bsky.social
Sharing a new data visualization exploring the phenotypic reprogramming of exhausted CD8+ T cells following PD-1 axis blockade.

#TcellExhaustion #CheckpointBlockade #TumorImmunology #CD8Tcells #AntiPD1 #Tpex #ImmuneCheckpoint #CancerImmunotherapy
Sharing a new data visualization exploring the phenotypic reprogramming of exhausted CD8+ T cells following PD-1 axis blockade. Figure: "Reprogramming exhausted CD8+ T cells with anti-PD-1 therapy" Subtitle: "Marker-defined transitions from terminal exhaustion toward progenitor/effector states after checkpoint blockade" The visualization employs a faceted marginal-distribution slope arrow design, functioning as a state-transition flow map. Each facet corresponds to a defined exhaustion-associated marker axis (TCF1, TOX, TIM-3, PD-1, GZMB, and Ki-67), with paired marginal distributions rendered pre- and post-treatment. Slope arrows connect the density centroids across conditions, encoding both the directionality and relative magnitude of population-level marker shifts. This approach was chosen to make explicit the differential mobilization of progenitor-exhausted (Tpex) versus terminally exhausted (Tex_term) subsets rather than collapsing the transition into a single trajectory summary. The simulated data are calibrated to reproduce trends consistent with the current literature. Under anti-PD-1, the TCF1+ TOX-intermediate progenitor compartment shows expansion accompanied by upward slope vectors in Ki-67 and GZMB, consistent with proliferative burst and reacquisition of effector potential. Concurrently, the TIM-3-high, TCF1-negative terminally differentiated fraction contracts, and its centroid displays limited displacement along the TCF1 axis, reflecting the constrained plasticity of terminally exhausted cells. This asymmetry underscores that checkpoint blockade preferentially acts on the Tpex reservoir rather than fully reverting terminal exhaustion, a distinction with direct implications for durability of response.
September 12, 2026 at 5:18 PM
iatlas-cri.bsky.social
The CRI iAtlas Immune Features module displays the distribution of immune readouts across your selected groups. In the image, we can see the estimates of T Cells CD4 for 5 datasets, with samples grouped based on the response to #ImmuneCheckpoint Inhibitor therapy. #immunotherapy
November 26, 2024 at 11:35 PM
iatlas-cri.bsky.social
The CRI iAtlas Immune Features module displays the distribution of immune readouts across your selected groups. In the image, we can see the estimates of T Cells CD4 for 5 datasets, with samples grouped based on the response to #ImmuneCheckpoint Inhibitor therapy. #immunotherapy
November 26, 2024 at 9:34 PM
bionewscentral.com
Drugs that suppress the ##UBA1 enzyme could make ##ImmuneCheckpoint blocking ##immunotherapy effective for patients with ##ProstateCancer and other ##ColdTumors.
Enzyme identified as new therapeutic target for cold tumors – BioNews Central
Drugs that suppress the UBA1 enzyme could make immune checkpoint blocking immunotherapy effective for patients with prostate cancer and other cold tumors. ...
sbee.link
December 5, 2024 at 1:12 AM
theinnovation.bsky.social
The RUNX1::RUNX1T1 pediatric AML model is a simple, robust tool for refining risk stratification. It effectively identifies a high-risk subset of patients with poor outcomes despite traditional favorable classification.
doi.org/10.1016/j.xi...
#acutemyeloidleukemia #medicine #immunecheckpoint
April 11, 2026 at 5:28 AM
prlennard.bsky.social
Check out this thread detailing the latest paper out of the Devil Lab where we investigated more #immunecheckpoint interactions 👇#TassieDevil #transendocytosis #cancer

x.com/WildImmunity/s… doi.org/10.1016/j.dci.…
January 23, 2025 at 1:46 PM
genesndiseases.bsky.social
This review highlights the CD47‑SIRPα axis as a key #ImmuneCheckpoint in #lymphoma, detailing current therapeutic strategies, including #FcFusionProteins and #peptides, and underscores their potential in treating Hodgkin and #NonHodgkinlymphomas.

#OpenAccess: doi.org/10.1016/j.ge...
December 4, 2025 at 5:25 PM
genesndiseases.bsky.social
Exciting read! Most downloaded article!

This review provides a comprehensive understanding of the #ImmuneMicroenvironment in #endometrialcarcinoma (EC) and elucidates the composition and functions of tumor-infiltrating immune cells. #ImmuneCheckpoint #medsky

#OpenAccess: buff.ly/KxlgQHt
June 7, 2025 at 4:30 PM